Indolent B-Cell Lymphoma
The latest news, research, and perspectives in indolent B-cell lymphoma. This diverse group of slow-growing non-Hodgkin lymphomas form in B cells and include follicular lymphoma, hairy cell leukemia, and marginal zone lymphoma.
Advertisement
September is Leukemia and Lymphoma Awareness Month, with Lymphoma Awareness Day marked on September 15.
The phase II study evaluated liso-cel in patients with relapsed or refractory follicular lymphoma.
The bispecific antibody mosunetuzumab in relapsed or refractory follicular lymphoma continues to show durable responses.
From Houston, Texas, to Beirut, Lebanon, the SOHO global community continues to grow thanks to its Ambassador Program.
The CAR-T targets both CD19 and CD20 antigens for the treatment of relapsed or refractory B-cell malignancies.
Dr. Dickinson discusses major updates to be presented during the 2023 European Hematology Association Congress.
Advertisement
Lisaftoclax alone or combined with ibrutinib/rituximab demonstrated measurable effects.
Pola-R-CHP and R-CHOP “demonstrated similar safety profiles” in older adults with previously untreated DLBCL.
The panel discusses new targets for DLBCL and FL and shares what excites them about the future for these diseases.
The panel discusses regulatory hurdles and patient access considerations for non-Hodgkin lymphoma therapies.
The panel discusses treatment sequencing after CAR-T or transplant and the role bispecifics and other regimens may play.
The panel discusses combination therapy options for patients with DLBCL and FL.
The panel discusses novel treatment options for FL, including bispecifics, CAR-Ts, monoclonal antibodies, and more.
The panel talks about novel therapies for DLBCL, including the timing and sequencing for such treatments and more.
The panel discusses barriers to improving treatment options for patients with DLBCL and follicular lymphoma.
A panel discusses the unmet needs and emerging therapeutic areas for DLBCL and follicular lymphoma.
At Blood Cancers Today, we have compiled the year's top content awards as doled out by the Twitterverse.
Manali Kamdar, MD; and Craig S. Sauter, MD, FACP; debate CAR T-cell therapy and AHSCT in second-line DLBCL.
Patients with LBCL received prophylactic anakinra to reduce the risk of cytokine release syndrome following CAR-T.
Orelabrutinib monotherapy may be an option for relapsed/refractory Waldenström’s macroglobulinemia.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDAssociate Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2023 Mashup Media, LLC. All rights reserved.